MitraClock for the discovery of skin longevity interventions in-vivo by Mitra Bio via ZOOM #33

Mitra Bio, a London-based startup, has developed a non-invasive skin epigenetic test that replaces invasive biopsies with a simple tape-stripping method to collect skin cells for the analysis of DNA methylation markers. By assessing biological skin age, inflammation, and UV damage, the test can be used for measuring epigenetic biomarkers before and after treatment, providing precise insight into skin health and longevity interventions.

Currently being used in more than 20 clinical studies, the test evaluates the effectiveness of topical skincare, energybased devices, supplements, and senolytic drugs.

Changes in DNA methylation – an important epigenetic modification – have been associated with aging and disease development. DNA methylation is a reversible modification that occurs in the human genome primarily on cytosines (5-methylcytosine) that are in a CpG dinucleotide context, and has been shown to exert a regulatory role on gene expression.

Mitra Bio is the first company to demonstrate the feasibility of using a tape stripping method combined with targeted methylation sequencing technology as a non-invasive approach to investigate DNA methylation changes in healthy skin.

At the center of Mitra Bio’s platform is MitraClock – the first skin-specific epigenetic clock that was trained exclusively on skin samples collected non-invasively from the human face.

MitraClock outperforms established epigenetic clocks in measuring skin aging with non-invasively collected samples. Using an adhesive-based tape-stripping technology for skin sample collection combined with a targeted methylation sequencing approach, MitraClock enables repeated and reliable epigenetic assessments, thus supporting the
development of personalised skincare as well as longevity interventions.

CONTACT

Shakiba Kaveh
shakiba@mitrabio.tech
https://mitrabio.tech/

👉 Read the ZOOM#33